Can we use disease burden to predict docetaxel activity in metastatic hormone-sensitive prostate cancer?

IF 1 Q4 PHARMACOLOGY & PHARMACY

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-02-12 DOI:10.1080/23808993.2020.1727739

M. Randhawa, Robert J. Jones

引用次数: 0

Abstract

One of the most important advances in the management of advanced prostate cancer in recent years, has been the utilization of drugs, previously reserved for those with metastatic castration-resista...

查看原文本刊更多论文

我们可以用疾病负担来预测转移性激素敏感前列腺癌的多西他赛活性吗?

近年来晚期前列腺癌治疗中最重要的进展之一是药物的使用，这些药物以前只用于转移性去势抵抗性前列腺癌患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Precision Medicine and Drug Development PHARMACOLOGY & PHARMACY-

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.